Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accounts Payables: 2012-2024

Historic Accounts Payables for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to $16.6 million.

  • Agios Pharmaceuticals' Accounts Payables rose 14.06% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 14.06%. This contributed to the annual value of $16.6 million for FY2024, which is 70.17% up from last year.
  • As of FY2024, Agios Pharmaceuticals' Accounts Payables stood at $16.6 million, which was up 70.17% from $9.8 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Accounts Payables peaked at $18.6 million during FY2022, and registered a low of $9.8 million during FY2023.
  • Over the past 3 years, Agios Pharmaceuticals' median Accounts Payables value was $16.6 million (recorded in 2024), while the average stood at $15.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first plummeted by 47.46% in 2023, then skyrocketed by 70.17% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Accounts Payables (Yearly) stood at $17.7 million in 2020, then declined by 5.78% to $16.7 million in 2021, then grew by 11.47% to $18.6 million in 2022, then tumbled by 47.46% to $9.8 million in 2023, then spiked by 70.17% to $16.6 million in 2024.